Research article · 19 Aug 2025
Conference abstractPublished 3 Jul 2017
The role of the PAK-1 inhibitor, Frondoside A in the treatment of cancer
United Arab Emirates University, UAE
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Frondoside A is a triterpenoid glycoside isolated from the edible sea cucumber Cucumaria frondosa. Frondoside A is an inhibitor of p21 activated kinase 1 (PAK-1). This compound has been shown to be an effective anti-cancer agent in leukemias and several solid malignancies, including pancreatic, colonic, breast, prostate and lung cancers with induction of apoptosis, as evidenced by morphological changes, annexin V binding, up-regulation of the cyclin-dependent kinase inhibitor p21waf1, up-regulation of proapototic proteins such as Bax, down-regulation of anti-apoptotic proteins such as Mcl-1 and Bcl2, activation of caspase 3, 6 and 9 activities and TUNEL assay. Frondoside A also inhibits invasion, metastases and angiogenesis in several models, potentiates the effects of other therapeutic agents, reduces multidrug resistance and shows anti-inflammatory and immunomodulatory effects with stimulation of innate immunity. Since PAK-1 activates multiple cellular pathways, including the ERK, p38 and Jnk mitogen-activated protein kinases (MAPK) and nuclear factor kappa B (NFÃ?ºB), this explains the broad spectrum of anti-cancer and anti-inflammatory properties of frondoside A. Frondoside A, does not have toxic effects at therapeutic doses, as evidenced by lack of change in CBC, liver function tests, body weight, etc. It has an LD50 of 9.9 mg/ kg in mice, which is 1000 times higher than the dose used therapeutically. Since its anticancer effects are not tissue specific Frondoside A may prove to be a valuable agent for the treatment for many malignant diseases.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Drug Designing: Open Access.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalDrug Designing: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Thomas E Adrian”
